Dallas, Texas 01/27/2014 (Financialstrend) – Zalicus Inc. (NASDAQ:ZLCS) the US based healthcare and biotechnology company is engaged in the development as well as discovery of new types of treatments for patients who suffer from various kinds of immuno-inflammatory diseases as well as pain.
Zalicus Inc. (NASDAQ:ZLCS) portfolio is largely clinical stage product candidates which are known to work well with other pharma companies for the production and discovery or other drug discovery technologies. The company now has a well-established revenue sharing and revenue generating collaborations with third parties.
Zalicus Inc. (NASDAQ:ZLCS) works on the development of selective ion channel modulators which will in combination with high throughput screening technology will help in the discovery of new product candidates for its own portfolio as well as for other third party products. The newer areas in which Zalicus Inc will see action along with pain, inflammation is oncology as well as infectious diseases.
Zalicus had seen sharp trading back in November, riding on heavy volume. The company had already seen the 10-day average volume double, though the shares had seen a slide earlier. One of Zalicus pet drugs, Z160 results, had proved to be a disappointment when it did not met the primary endpoint during the Phase 2 trials. Z160 discontinuation will now move the the focus, to Z944, which is expected to now going into testing any time in 2014. Z160 had not met any of the primary endpoints expected of it.
Zalicus Inc.(NASDAQ:ZLCS) currently trades on the stock market between price ranges of $1.62 and $1.82 on a daily range basis.. The 52 week range for the stock is between $0.88 and $8.28. The volume is $1.79 million and the market capital is $42.79million. The EPS for Zalicus Inc is -1.72 with beta at 1.69.
DISCLOSURE: The views and opinions expressed in this article are those of the authors, and do not represent the views of financialstrend.com. Readers should not consider statements made by the author as formal recommendations and should consult their financial advisor before making any investment decisions. To read our full disclosure, please go to: